GlassScriptPhysician profile
Walter P Harris
NPI 1689730905
$3,269.80
in general payments reported to CMS, 2019-2025
22 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $268 · 2021: $237 · 2022: $606 · 2023: $276 · 2024: $617 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $450.18 | 2021-2025 | |
| Alcon Vision LLC | $445.64 | 2019-2025 | Rocklatan, Argos, Clareon Panoptix Pro |
| Sight Sciences, INC. | $407.48 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $354.55 | 2022-2025 | |
| New World Medical,INC. | $250.30 | 2022-2025 | Via360, Streamline, Kahook Dual Blade |
| Bausch & Lomb Americas INC. | $246.19 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $200.72 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $171.20 | 2023-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $91.03 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $86.21 | 2019-2023 | |
| Amgen INC. | $77.67 | 2024-2025 | Uplizna, Tepezza |
| Sun Pharmaceutical Industries INC. | $76.82 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $69.67 | 2019-2021 | |
| Allergan, INC. | $58.48 | 2020-2021 | |
| Dompe US, INC. | $54.52 | 2022-2025 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $53.23 | 2025 | Amo Phaco Needle, Tecnis Iol |
| Horizon Therapeutics Plc | $49.10 | 2023 | Uplizna |
| Johnson & Johnson Vision Care, INC. | $37.90 | 2025 | |
| Harrow Eye, LLC | $26.06 | 2025 | Vevye |
| Shire North American Group INC | $24.77 | 2019 | |
| Argenx US, INC. | $21.89 | 2025 | Vyvgart |
| Akorn, INC. | $16.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.